These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 39046432

  • 1. Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation.
    Feng L, Hu W, Zeng X, Wei Z, Long Y, Li M, Sun S, Guo Z, Lan X, Zhang X, Zhuang R, Jiang D.
    Mol Pharm; 2024 Sep 02; 21(9):4386-4394. PubMed ID: 39046432
    [Abstract] [Full Text] [Related]

  • 2. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2.
    Läppchen T, Bilinska A, Pilatis E, Menéndez E, Imlimthan S, Moon ES, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E.
    Molecules; 2024 Jun 28; 29(13):. PubMed ID: 38999044
    [Abstract] [Full Text] [Related]

  • 3. 68Ga/177Lu-Labeled Theranostic Pair for Targeting Fibroblast Activation Protein with Improved Tumor Uptake and Retention.
    Huang J, Zhang X, Liu Q, Gong F, Huang Y, Huang S, Fu L, Tang G.
    J Med Chem; 2024 Oct 10; 67(19):17785-17795. PubMed ID: 39321030
    [Abstract] [Full Text] [Related]

  • 4. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T, Peng L, Qiu J, He X, Zhang D, Wu R, Liu J, Zhang X, Zha Z.
    Eur J Nucl Med Mol Imaging; 2023 Jul 10; 50(8):2331-2341. PubMed ID: 36864362
    [Abstract] [Full Text] [Related]

  • 5. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y, Zhao L, Fang J, Chen J, Meng L, Sun L, Wu H, Guo Z, Lin Q, Chen H.
    J Nucl Med; 2023 Sep 10; 64(9):1449-1455. PubMed ID: 37321827
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
    Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, Liu Z.
    Eur J Nucl Med Mol Imaging; 2022 May 10; 49(6):1985-1996. PubMed ID: 34746969
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.
    Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U.
    J Nucl Med; 2019 Mar 10; 60(3):386-392. PubMed ID: 30072500
    [Abstract] [Full Text] [Related]

  • 11. Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy.
    Lindner T, Altmann A, Krämer S, Kleist C, Loktev A, Kratochwil C, Giesel F, Mier W, Marme F, Debus J, Haberkorn U.
    J Nucl Med; 2020 Oct 10; 61(10):1507-1513. PubMed ID: 32169911
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [68Ga]Ga-labeled FAPI Conjugated with Gly-Pro Sequence for PET Imaging of Malignant Tumors.
    Shang Y, Zhang G, Yao X, Lai C, Wang F, Zeng B, Liu E, Yuan H, Cheng Z, Jiang L.
    Mol Imaging Biol; 2024 Aug 10; 26(4):729-737. PubMed ID: 38987449
    [Abstract] [Full Text] [Related]

  • 16. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
    Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, Shi C, Li J, Guo Z, Zhang X, Khong PL, Chen X.
    Theranostics; 2022 Aug 10; 12(1):422-433. PubMed ID: 34987657
    [Abstract] [Full Text] [Related]

  • 17. 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.
    Ding J, Xu M, Chen J, Zhang P, Huo L, Kong Z, Liu Z.
    Mol Pharm; 2022 Sep 05; 19(9):3429-3438. PubMed ID: 35976352
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics.
    Zhong X, Guo J, Han X, Wu W, Yang R, Zhang J, Shao G.
    Mol Pharm; 2023 May 01; 20(5):2402-2414. PubMed ID: 37015025
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
    Lai C, Cao R, Li R, He C, Wang X, Shi H, Qu C, Qian K, Song S, Chen WH, Cheng Z.
    Mol Pharm; 2023 Aug 07; 20(8):4120-4128. PubMed ID: 37487027
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.